UpdatesPress Release
Astec LifeSciences reported Q1FY27 consolidated total income of ₹84.3 Cr, down 8%. Despite lower revenue, the company achieved EBITDA breakeven at ₹0.1 Cr, reducing loss to ₹18.7 Cr.
Astec LifeSciences LimitedASTEC · Filed with the exchange
This improvement was driven by a favorable product mix and enhanced capacity utilization.
No comments yet. Be the first.